Introduction

When patients first hear the diagnosis "macular degeneration," the question is often immediate and anxious: Can it be reversed? It's a deeply human reaction. After all, the macula—the central part of the retina—governs our ability to read, recognize faces, and see fine details. The prospect of losing that clarity is frightening.

At Global Ubal Eye Center in Incheon, South Korea, we hear this concern often. As a leading ophthalmology clinic with more than two decades of experience, we understand the urgency behind the question. So let’s explore the reality: what treatments are available, what reversal truly means in this context, and how ongoing advances may change the picture in the years ahead.

What Is Macular Degeneration?

Age-related macular degeneration (AMD) is a progressive eye disease that primarily affects the macula—the central portion of the retina responsible for sharp, detailed vision. This region allows us to read small print, distinguish faces, and see fine details when driving or performing close-up tasks. When the macula deteriorates, central vision becomes blurred or distorted, while peripheral vision remains largely unaffected.

AMD is the leading cause of vision loss among older adults worldwide, and its prevalence is growing as populations age. The disease typically begins subtly, often going unnoticed in its early stages. Many patients first notice a blurry or dark spot in the center of their vision, or straight lines that appear wavy.

There are two primary forms of AMD:

• Dry AMD (atrophic): The most common form, accounting for about 85–90% of cases. It occurs when the macular tissue gradually thins with age and drusen (tiny yellow deposits) build up under the retina. Vision loss progresses slowly but steadily over time.
• Wet AMD (neovascular): A more severe and fast-progressing form. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging macular cells. Without prompt treatment, wet AMD can lead to sudden and profound vision loss.

Although AMD does not cause complete blindness, the loss of central vision can severely affect daily life—impacting reading, driving, and recognizing faces. Because of its gradual nature, regular eye exams are essential for early detection and timely intervention.

Can AMD Be Reversed?

The human retina is an extraordinarily delicate and highly specialized structure. The macula, in particular, is composed of photoreceptor cells and supporting tissue that do not regenerate naturally. Unlike the skin or liver, the retina lacks the ability to heal itself once cells are lost. For this reason, even the most sophisticated treatments cannot fully reverse damage that has already occurred.

This leads to an important clarification. While many patients ask if AMD can be “reversed,” what they are often seeking is a return to their prior level of vision. In medical terms, a more appropriate goal is disease remission or functional stabilization. That means stopping further damage, preserving existing vision, and—in some cases—improving it slightly with treatment.

For example, in wet AMD, anti-VEGF therapies can reduce swelling and leakage, leading to clearer vision. Some patients report dramatic improvements, regaining the ability to read or drive. But this is not a reversal in the structural sense; rather, it’s a restoration of function despite underlying damage.

Current Treatments for Dry AMD

AREDS2 Supplements

A large-scale clinical study (Age-Related Eye Disease Study 2) showed that a specific combination of antioxidants and zinc could reduce the risk of progression from intermediate to advanced dry AMD by about 25%. It won’t cure AMD, but it can preserve vision longer.

Photobiomodulation

This non-invasive therapy uses low-level red and near-infrared light to reduce inflammation and oxidative stress in retinal cells. It may improve contrast sensitivity and slow progression in dry AMD.

New Injections: Izervay and Syfovre

Recently approved drugs like avacincaptad pegol (Izervay) and pegcetacoplan (Syfovre) represent major steps forward. These complement inhibitors can slow the expansion of geographic atrophy, an advanced form of dry AMD. While they require regular injections, they mark a new era in managing what was previously untreatable.

Current Treatments for Wet AMD

Anti-VEGF Injections

Medications like Eylea, Lucentis, and Vabysmo are injected into the eye to stop the growth of abnormal blood vessels. These treatments have revolutionized wet AMD care, allowing 90% of patients to maintain their vision and up to 30% to experience meaningful improvement.

Extended-Release Systems

The Susvimo port delivery system offers a longer-lasting solution. Implanted in the eye, it continuously releases medication over several months, reducing the frequency of injections.

New Generation Drugs

Faricimab (Vabysmo) targets two disease pathways (VEGF and Ang-2), providing more durable results. High-dose versions of Eylea are also allowing patients to stretch their treatment intervals up to 16 weeks without compromising efficacy.

Emerging and Experimental Therapies

Stem Cell Therapy

Researchers are exploring how embryonic or induced pluripotent stem cells might be used to regenerate retinal pigment epithelium (RPE). Early trials have shown safety and potential for modest visual improvement, though widespread application remains years away.

Gene Therapy

Projects like RGX-314 and ADVM-022 deliver genes that code for anti-VEGF agents directly into the eye. In theory, this could eliminate the need for regular injections, as the eye becomes its own drug factory. Some patients in trials have gone over 18 months without additional treatment.

Senolytic Agents

Drugs like Foselutoclax (UBX1325) are being developed to remove senescent (aged and non-functioning) cells that contribute to retinal inflammation. Early studies in AMD and diabetic eye disease are showing promise.

Novel Approaches

Research on Apolipoprotein M (ApoM) and cellular reprogramming offers longer-term visions of reversing retinal damage before it becomes permanent. These are not yet ready for clinic use, but they illustrate how AMD care may change dramatically over the next decade.

What We Recommend at Global Ubal Eye Center

We approach AMD with long-term, personalized care. Every patient receives comprehensive retinal imaging and visual function testing. Depending on your stage and type of AMD, we may recommend:

• Immediate anti-VEGF treatment for wet AMD to halt rapid progression
• AREDS2 supplementation for dry AMD patients at risk of progression
• Referral for low-vision rehabilitation when needed
• Nutritional and lifestyle counseling including smoking cessation, dietary changes, and UV protection
• Monitoring and early enrollment in clinical trials when suitable

As a multilingual clinic welcoming international patients, we also provide full interpretation and care coordination in Korean, English, Japanese, Mongolian, and Russian.

Conclusion

Macular degeneration cannot yet be reversed in the way many people hope. The complexity of retinal tissue and the irreversible nature of advanced damage make full recovery unlikely with today’s therapies. But that doesn't mean there is no hope.

AMD is a manageable condition. With early diagnosis, lifestyle changes, nutritional support, and access to the latest medical treatments, many patients retain useful vision for years. For wet AMD in particular, current therapies can even lead to measurable improvement in vision and quality of life.

The field of ophthalmology continues to evolve rapidly. New technologies, from stem cell applications to gene therapies, hint at a future where reversal may become more than just a dream.

At Global Ubal Eye Center, we are committed to staying at the forefront of this evolution—combining precision medicine with patient-first care. If you’re concerned about changes in your central vision or know someone who is, we encourage you to take action. The earlier AMD is addressed, the more options you have for protecting your sight.